Exploration of nonclinical pharmacodynamics evaluation system of Alzheimer's disease
10.16438/j.0513-4870.2019-0899
- VernacularTitle:抗阿尔茨海默病药物非临床药效学评价体系的探索
- Author:
Long-jian HUANG
1
;
Chun-yang ZHAO
2
;
Xin-hong FENG
3
;
Jia-qi LAN
1
;
Jing-shu TANG
1
;
Qing-li WANG
2
;
Ying PENG
1
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Center for Drug Evaluation, National Medical Product Administration, Beijing 100022, China
3. Department of Neurology, Beijing Tsinghua Changgung Hospital, Beijing 102218, China
- Publication Type:Research Article
- Keywords:
Alzheimer's disease;
animal model;
behavioristics;
non-clinical pharmacodynamics;
rug discovery
- From:
Acta Pharmaceutica Sinica
2020;55(5):789-805
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease (AD) is the most common neurodegenerative disease that causes dementia among elderly people. The pathogenesis of AD is still unclear, and currently approved drugs only provide symptomatic benefits and do not prevent or delay progressive neurodegeneration. Meanwhile, potential drugs in development are facing great challenges in clinical translation. Therefore, finding effective treatment for the unmet clinical needs of AD is of great economic value and social significance. In this review, we will summarize the current models and pharmacodynamics evaluation methods of anti-AD drug based on the recent studies at home and abroad, and provide reference for drug development in AD at nonclinical stage.
